Comparative Study of the Effect of Growth Hormone on Left Ventricular Ejection Fraction and Thickness among Patients Suffering from Ischemic Heart Failure: A Randomized Double-Blinded Clinical Trial Study

Based on the previous studies, stem cells have been proved to be activated within 4 weeks after myocardial infarction (MI) by growth hormone (GH). In this study, we aimed to assess the relation of 3 months of GH prescription on left ventricular ejection fraction (LVEF), and thickness of interventricular septum (IVS) and posterior left ventricle (LV) among Iranian individuals suffering from heart failure because of their first MI attack.

16 clinically stable patients with history of MI suffering from heart failure with LVEF < 40% were eligible for enrollment in this randomized clinical trial study. They were randomly assigned to groups receiving 5 mg subcutaneous GH (n = 8) or placebo (n = 8) with injections done each other day for 3 months. Cardiac outcomes including LVEF, and thickness of IVS and posterior LV were assessed at the end of the intervention.

LVEF was remarkably increased by three months started from baseline of 32 ± 3.80 percent in patients receiving GH to 43.80 ± 4.60 percent (P = 0.002). Moreover, LVEF was significantly higher in participants receiving GH (43.80 ± 4.60 percent) compared with placebo group (33.14 ± 4.84 percent) at the end of trial (P = 0.003). IVS or posterior LV wall thickness failed to prove any considerable associations in GH or placebo groups.

 Our outcomes revealed that GH administration was associated with raised LVEF function among the patients with heart failure due to MI attack.</div>